Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Naked Shorting Continues

<< Previous

Bullboard Posts

Next >>

Post by Arbourmarkon Jan 04, 2022 11:18am

198 Views

Post# 34281712

Naked Shorting Continues

We get news release today x as nd share price drops 5%. The same daily pattern continues with the same houses using dark pool trades knock share price lower on low volume.

CIBC and Anonymous are some two involved on this daily trading pattern to knock share price lower. Naked shorting should be investigated but unfortunately in Canada our watch dogs like IRROC and OSC seem to turn a blind eye.

I unfortunately feel this trading pattern will continue until the detailed third party analysis of phase 2 results are released.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario